Abstract | UNLABELLED: Primary axillary hyperhidrosis is a disorder affecting mainly adolescents with significant adverse effects on quality of life. No ideal treatment exists, although recent data has demonstrated Botulinum toxin type A ( Botox) as a treatment option. However, antibody formation may lead to loss of clinical benefit over time. Botulinum toxin type B ( Neurobloc) has recently been introduced and may induce less immunogenic response. OBJECTIVE: METHOD: Thirteen patients (22 axillae) were recruited to the study. The hyperhidrotic area was defined using the iodine- starch test then measured and photographed. 5000 MU of Neurobloc was administered subdermally. Patients were reviewed at 4, 8 and 12 weeks to assess outcome objectively (hyperhidrotic area measurements and photographs) and subjectively (sweat production and patient satisfaction). RESULTS: There was a significant reduction in hyperhidrotic area at follow-up compared to baseline. Mean percentage reduction in hyperhidrotic area was 84, 87 and 81% at 4, 8 and 12 weeks (p=0.001, paired t test). Patient satisfaction was 100% throughout. Subjective mean percentage reduction in sweat production was 98, 96 and 90 at 4, 8 and 12 weeks. Side effects were minimal. CONCLUSION:
|
Authors | L Nelson, P Bachoo, J Holmes |
Journal | British journal of plastic surgery
(Br J Plast Surg)
Vol. 58
Issue 2
Pg. 228-32
(Mar 2005)
ISSN: 0007-1226 [Print] England |
PMID | 15710119
(Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Neuromuscular Blocking Agents
- rimabotulinumtoxinB
- Botulinum Toxins
- Botulinum Toxins, Type A
|
Topics |
- Adult
- Axilla
- Botulinum Toxins
(therapeutic use)
- Botulinum Toxins, Type A
- Female
- Humans
- Hyperhidrosis
(drug therapy)
- Male
- Neuromuscular Blocking Agents
(therapeutic use)
- Pilot Projects
- Treatment Outcome
|